Literature DB >> 16608662

When to start antiretroviral therapy.

Cunlin Wang1, Saba W Masho, Daniel E Nixon.   

Abstract

The current literature is controversial in providing evidence to determine the optimal time to initiate therapy among patients with HIV. However, there is evidence that initiating early treatment might provide benefits by treating primary HIV infection, preserving normal immune function, suppressing HIV viral replication, deferring clinical progression, and reducing HIV transmission. The biggest challenges in initiating treatment early are issues related with long-term management, including toxicities, adherence, and drug resistance. However, the availability of superior new antiretroviral drugs and simplified regimens, the development of effective treatment strategy, and further improvement of adherence through directly observed treatment are addressing the issues and changing the balance towards earlier treatment.

Entities:  

Mesh:

Year:  2006        PMID: 16608662     DOI: 10.1007/s11904-006-0020-3

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  64 in total

1.  CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection.

Authors:  Christoph G Lange; Hernan Valdez; Kathy Medvik; Robert Asaad; Michael M Lederman
Journal:  Clin Immunol       Date:  2002-02       Impact factor: 3.969

2.  Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.

Authors:  Isabelle Pellegrin; Rodolphe Thiébaut; Patrick Blanco; Jean-François Viallard; Marie-Hélène Schrive; Patrick Merel; Geneviève Chêne; Hervé Fleury; Jean-François Moreau; Jean-Luc Pellegrin
Journal:  J Med Virol       Date:  2005-10       Impact factor: 2.327

3.  Ten years of HAART.

Authors:  Mark Harrington
Journal:  Res Initiat Treat Action       Date:  2005

4.  HIV antiretroviral treatment: early versus later.

Authors:  Josephine Mauskopf; Mari Kitahata; Teresa Kauf; Anke Richter; Jerry Tolson
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-15       Impact factor: 3.731

5.  Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.

Authors:  Manuel L Fernández Guerrero; Pablo Rivas; Mercedes Molina; Rosa Garcia; Miguel De Górgolas
Journal:  Clin Infect Dis       Date:  2005-06-22       Impact factor: 9.079

6.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Authors:  A N Phillips; S Staszewski; R Weber; O Kirk; P Francioli; V Miller; P Vernazza; J D Lundgren; B Ledergerber
Journal:  JAMA       Date:  2001-11-28       Impact factor: 56.272

7.  Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users.

Authors:  M Prins; I H Hernández Aguado; R P Brettle; J R Robertson; B Broers; N Carré; D J Goldberg; R Zangerle; R A Coutinho; A van den Hoek
Journal:  AIDS       Date:  1997-11-15       Impact factor: 4.177

8.  Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.

Authors:  F Maggiolo; M Migliorino; R Maserati; A Pan; M Rizzi; G Provettoni; L Rizzi; F Suter
Journal:  Antivir Ther       Date:  2001-12

Review 9.  Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

Authors:  Paula Braitstein; Anita Palepu; Douglas Dieterich; Yves Benhamou; Julio S G Montaner
Journal:  AIDS       Date:  2004-11-19       Impact factor: 4.177

10.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

View more
  1 in total

1.  Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Authors:  Abdel G Babiker; Sean Emery; Gerd Fätkenheuer; Fred M Gordin; Birgit Grund; Jens D Lundgren; James D Neaton; Sarah L Pett; Andrew Phillips; Giota Touloumi; Michael J Vjechaj
Journal:  Clin Trials       Date:  2012-04-30       Impact factor: 2.486

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.